Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus
Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus
复制标题
DOI：
10.1089/jmf.2017.0114
复制
发表时间：
2018-02-12
影响因子：
2.4
通讯作者：
Mendez-del Villar, Miriam
中科院分区：
文献类型：
--
作者：
Cortez-Navarrete, Marisol;Martinez-Abundis, Esperanza;Mendez-del Villar, Miriam
观察到苦瓜可改善2型糖尿病（T2 DM）患者的血糖控制参数。目前尚不清楚这种改善是否是通过胰岛素分泌，胰岛素敏感性或两者的修饰。我们假设M。Charantia给药可改善T2 DM患者的胰岛素分泌和/或胰岛素敏感性，无需药物治疗。本研究的目的是评价M. charantia给药对胰岛素分泌和敏感性的影响。一项随机、双盲、安慰剂对照的临床试验在24例接受M。Charantia（2000 mg/天）或安慰剂治疗3个月。干预前后进行2 h口服葡萄糖耐量试验（OGTT），计算血糖和胰岛素曲线下面积（AUC）、总胰岛素分泌（胰岛素生成指数）、胰岛素分泌第一时相（Stumvoll指数）和胰岛素敏感性（Matsuda指数）。在机动Charantia组体重、体重指数（BMI）、脂肪百分比、腰围（WC）、糖化血红蛋白A1 c（A1 C）、OGTT 2 h血糖和血糖AUC均显著降低。胰岛素AUC显著增加（56，562 +/-36，078 vs. 65，256 +/-42，720 pmol/L/min，P = 0.043），总胰岛素分泌（0.29-0.18 vs. 0.41 +/- 0.29，P = 0.028），在M后胰岛素分泌的第一阶段（557.8 +/- 645.6 vs. 1135.7 +/- 725.0，P = 0.043）观察到。charantia管理。胰岛素敏感性没有改变任何干预。最后，M. charantia给药降低了A1 C、2-h葡萄糖、葡萄糖AUC、体重、BMI、脂肪百分比和WC，增加了胰岛素AUC、第一时相和总胰岛素分泌。
An improvement in parameters of glycemic control has been observed with Momordica charantia in patients with type 2 diabetes mellitus (T2DM). It is unknown whether this improvement is through a modification of insulin secretion, insulin sensitivity, or both. We hypothesized that M. charantia administration can improve insulin secretion and/or insulin sensitivity in patients with T2DM, without pharmacological treatment. The objective of the study was to evaluate the effect of M. charantia administration on insulin secretion and sensitivity. A randomized, double-blinded, placebo-controlled, clinical trial was carried out in 24 patients who received M. charantia (2000 mg/day) or placebo for 3 months. A 2-h oral glucose tolerance test (OGTT) was done before and after the intervention to calculate areas under the curve (AUC) of glucose and insulin, total insulin secretion (insulinogenic index), first phase of insulin secretion (Stumvoll index), and insulin sensitivity (Matsuda index). In the M. charantia group, there were significant decreases in weight, body mass index (BMI), fat percentage, waist circumference (WC), glycated hemoglobin A1c (A1C), 2-h glucose in OGTT, and AUC of glucose. A significant increase in insulin AUC (56,562 +/- 36,078 vs. 65,256 +/- 42,720 pmol/L/min, P =.043), in total insulin secretion (0.29-0.18 vs. 0.41 +/- 0.29, P =.028), and during the first phase of insulin secretion (557.8 +/- 645.6 vs. 1135.7 +/- 725.0, P =.043) was observed after M. charantia administration. Insulin sensitivity was not modified with any intervention. In conclusion, M. charantia administration reduced A1C, 2-h glucose, glucose AUC, weight, BMI, fat percentage, and WC, with an increment of insulin AUC, first phase and total insulin secretion.